Research progress of liquid biopsy technology in esophageal squamous cell carcinoma

doi:10.3760/cma.j.cn371439-20230621-00015

Abstract

Abstract:

In recent years，with the continuous development of biotechnology，liquid biopsy techno-logy has gradually become a research hotspot in the field of tumor research. As a non-invasive diagnostic method，liquid biopsy has great advantages compared with traditional methods. The liquid biopsy technology is precise，convenient，non-invasive and safe，and has an increasingly important clinical significance in the early diagnosis，treatment and prognosis assessment of esophageal squamous cell carcinoma.

Key words: Esophageal squamous cell carcinoma, Neoplastic cells, circulating, Exosomes, Circula-ting tumor DNA, Circulating tumor RNA

Liu Bohan, Huang Junxing. Research progress of liquid biopsy technology in esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2024, 51(2): 105-108.

References 30

[1]	He Z, Ke Y. Precision screening for esophageal squamous cell carcinoma in China[J]. Chin J Cancer Res, 2020, 32(6): 673-682. DOI: 10.21147/j.issn.1000-9604.2020.06.01.
[2]	Shah MA, Kennedy EB, Catenacci DV, et al. Treatment of locally advanced esophageal carcinoma: ASCO guideline[J]. J Clin Oncol, 2020, 38(23): 2677-2694. DOI: 10.1200/JCO.20.00866. pmid: 32568633
[3]	Wu C, Zhang J, Li H, et al. The potential of liquid biopsies in gastrointestinal cancer[J]. Clin Biochem, 2020, 84: 1-12. DOI: 10.1016/j.clinbiochem.2020.06.007. pmid: 32540214
[4]	Shi Y, Ge X, Ju M, et al. Circulating tumor cells in esophageal squamous cell carcinoma-mini review[J]. Cancer Manag Res, 2021, 13: 8355-8365. DOI: 10.2147/CMAR.S337489.
[5]	Choi MK, Kim GH, I H, et al. Circulating tumor cells detected using fluid-assisted separation technique in esophageal squamous cell carcinoma[J]. J Gastroenterol Hepatol, 2019, 34(3): 552-560. DOI: 10.1111/jgh.14543.
[6]	Han L, Li YJ, Zhang WD, et al. Clinical significance of tumor cells in the peripheral blood of patients with esophageal squamous cell carcinoma[J]. Medicine (Baltimore), 2019, 98(6): e13921. DOI: 10.1097/MD.0000000000013921.
[7]	Zhao Y, Han L, Zhang W, et al. Preoperative chemotherapy compared with postoperative adjuvant chemotherapy for squamous cell carcinoma of the thoracic oesophagus with the detection of circula-ting tumour cells randomized controlled trial[J]. Int J Surg, 2020, 73: 1-8. DOI: 10.1016/j.ijsu.2019.11.005.
[8]	Lee HJ, Kim GH, Park SJ, et al. Clinical significance of TWIST-positive circulating tumor cells in patients with esophageal squamous cell carcinoma[J]. Gut Liver, 2021, 15(4): 553-561. DOI: 10.5009/gnl20194. pmid: 33293482
[9]	Kok VC, Yu CC. Cancer-derived exosomes: their role in cancer biology and biomarker development[J]. Int J Nanomedicine, 2020, 15: 8019-8036. DOI: 10.2147/IJN.S272378.
[10]	Luo A, Zhou X, Shi X, et al. Exosome-derived miR-339-5p me-diates radiosensitivity by targeting Cdc25A in locally advanced esophageal squamous cell carcinoma[J]. Oncogene, 2019, 38(25): 4990-5006. DOI: 10.1038/s41388-019-0771-0.
[11]	Qiu ML, Li X, Lin JB, et al. Serum exosomal miR-182 upregulation predicts unfavorable prognosis of esophageal squamous cell carcinoma[J]. Eur Rev Med Pharmacol Sci, 2020, 24(10): 5412-5418. DOI: 10.26355/eurrev_202005_21325.
[12]	Li P, Liu X, Xing W, et al. Exosome-derived miR-200a promotes esophageal cancer cell proliferation and migration via the media-ting Keap1 expression[J]. Mol Cell Biochem, 2022, 477(4): 1295-1308. DOI: 10.1007/s11010-022-04353-z.
[13]	Liu Z, Huang Y, Han Z, et al. Exosome-mediated miR-25/miR-203 as a potential biomarker for esophageal squamous cell carcinoma: improving early diagnosis and revealing malignancy[J]. Transl Cancer Res, 2021, 10(12): 5174-5182. DOI: 10.21037/tcr-21-1123. pmid: 35116367
[14]	Han GL, Wang J, Guo K, et al. MiRNA-574-5p downregulates ZNF70 and influences the progression of human esophageal squamous cell carcinoma through reactive oxygen species generation and MAPK pathway activation[J]. Anticancer Drugs, 2020, 31(3): 282-291. DOI: 10.1097/CAD.0000000000000833. pmid: 32053575
[15]	Li K, Lin Y, Luo Y, et al. A signature of saliva-derived exosomal small RNAs as predicting biomarker for esophageal carcinoma: a multicenter prospective study[J]. Mol Cancer, 2022, 21(1): 21. DOI: 10.1186/s12943-022-01499-8. pmid: 35042519
[16]	Lin Y, Dong H, Deng W, et al. Evaluation of salivary exosomal chimeric GOLM1-NAA35 RNA as a potential biomarker in esophageal carcinoma[J]. Clin Cancer Res, 2019, 25(10): 3035-3045. DOI: 10.1158/1078-0432.CCR-18-3169.
[17]	Yan L, Dong X, Gao J, et al. A novel rapid quantitative method reveals stathmin-1 as a promising marker for esophageal squamous cell carcinoma[J]. Cancer Med, 2018, 7(5): 1802-1813. DOI: 10.1002/cam4.1449.
[18]	Chen M, Zhao H. Next-generation sequencing in liquid biopsy: cancer screening and early detection[J]. Hum Genomics, 2019, 13(1): 34. DOI: 10.1186/s40246-019-0220-8. pmid: 31370908
[19]	Pessoa LS, Heringer M, Ferrer VP. ctDNA as a cancer biomarker: a broad overview[J]. Crit Rev Oncol Hematol, 2020, 155: 103109. DOI: 10.1016/j.critrevonc.2020.103109.
[20]	Liu T, Yao Q, Jin H. Plasma circulating tumor DNA sequencing predicts minimal residual disease in resectable esophageal squamous cell carcinoma[J]. Front Oncol, 2021, 11: 616209. DOI: 10.3389/fonc.2021.616209.
[21]	Morimoto Y, Matsuda S, Kawakubo H, et al. Tumor burden monitoring with circulating tumor DNA during treatment in patients with esophageal squamous cell carcinoma[J]. Ann Surg Oncol, 2023, 30(6): 3747-3756. DOI: 10.1245/s10434-023-13194-z. pmid: 36788188
[22]	Wang X, Yu N, Cheng G, et al. Prognostic value of circulating tumour DNA during post-radiotherapy surveillance in locally advanced esophageal squamous cell carcinoma[J]. Clin Transl Med, 2022, 12(11): e1116. DOI: 10.1002/ctm2.1116. pmid: 36437506
[23]	Jia R, Zhao CH, Li PS, et al. Post-radiation circulating tumor DNA as a prognostic factor in locally advanced esophageal squamous cell carcinoma[J]. Oncol Lett, 2021, 21(1): 68. DOI: 10.3892/ol.2020.12329. pmid: 33365079
[24]	Feng Q, Zhang H, Yao D, et al. Emerging role of non-coding RNAs in esophageal squamous cell carcinoma[J]. Int J Mol Sci, 2019, 21(1): 258. DOI: 10.3390/ijms21010258.
[25]	De Rubis G, Rajeev Krishnan S, Bebawy M. Liquid biopsies in cancer diagnosis, monitoring, and prognosis[J]. Trends Pharmacol Sci, 2019, 40(3): 172-186. DOI: 10.1016/j.tips.2019.01.006. pmid: 30736982
[26]	Si W, Shen J, Zheng H, et al. The role and mechanisms of action of microRNAs in cancer drug resistance[J]. Clin Epigenetics, 2019, 11(1): 25. DOI: 10.1186/s13148-018-0587-8. pmid: 30744689
[27]	Han L, Cui D, Li B, et al. MicroRNA-338-5p reverses chemoresistance and inhibits invasion of esophageal squamous cell carcinoma cells by targeting Id-1[J]. Cancer Sci, 2019, 110(12): 3677-3688. DOI: 10.1111/cas.14220.
[28]	Szilágyi M, Pös O, Márton É, et al. Circulating cell-free nucleic acids: main characteristics and clinical application[J]. Int J Mol Sci, 2020, 21(18): 6827. DOI: 10.3390/ijms21186827.
[29]	Sharma U, Barwal TS, Khandelwal A, et al. Circulating long non-coding RNAs LINC00324 and LOC100507053 as potential liquid biopsy markers for esophageal squamous cell carcinoma: a pilot study[J]. Front Oncol, 2022, 12: 823953. DOI: 10.3389/fonc.2022.823953.
[30]	Luo D, Huang Z, Lv H, et al. Up-regulation of microRNA-21 indicates poor prognosis and promotes cell proliferation in esophageal squamous cell carcinoma via upregulation of lncRNA SNHG1[J]. Cancer Manag Res, 2020, 12: 1-14. DOI: 10.2147/CMAR.S221731. pmid: 32021418